Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections (CORONAVIT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT04579640

Recruitment Status : Completed

First Posted : October 8, 2020

Last Update Posted : April 6, 2022

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Barts & The London NHS Trust

Pharma Nord

Fischer Family Trust

The AIM Foundation

Synergy Biologics Ltd

Cytoplan Ltd

Information provided by (Responsible Party):

Queen Mary University of London

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	June 17, 2021
Actual Study Completion Date :	February 28, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Jolliffe DA, Holt H, Greenig M, Talaei M, Perdek N, Pfeffer P, Vivaldi G, Maltby S, Symons J, Barlow NL, Normandale A, Garcha R, Richter AG, Faustini SE, Orton C, Ford D, Lyons RA, Davies GA, Kee F, Griffiths CJ, Norrie J, Sheikh A, Shaheen SO, Relton C, Martineau AR. Effect of a test-and-treat approach to vitamin D supplementation on risk of all cause acute respiratory tract infection and covid-19: phase 3 randomised controlled trial (CORONAVIT). BMJ. 2022 Sep 7;378:e071230. doi: 10.1136/bmj-2022-071230.

To Top